BioCentury
ARTICLE | Clinical News

Nimbus Discovery preclinical data

December 17, 2012 8:00 AM UTC

In human peripheral blood mononuclear cells (PBMCs) and activated B cell-like DLBCL cell lines, ND-2110 suppressed secretion of IL-6 and IL-10. Furthermore, Nimbus said ND-2110 plus ibrutinib synergistically induced selective cell death in hematologic tumors with the activating myeloid differentiation primary response gene 88 (MYD88) mutation in multiple DLBCL cell lines. Data were presented at the American Society of Hematology meeting in Atlanta. Nimbus plans to start clinical testing of ND-2110, an IL-1 receptor-associated kinase 4 ( IRAK4) inhibitor, to treat patients with hematologic tumors in 2014. ...